Tumors Expressing Fibroblast Activation Protein (FAP)
This condition refers to certain tumors, including carcinomas and sarcomas, that express Fibroblast Activation Protein (FAP) on their stroma or tumor cells, which may influence treatment options.
Advanced Solid Tumors: OMTX705 Treatment
We are testing a new antibody-drug conjugate for patients with advanced solid tumors. The study looks at its effects alone and in combination with another treatment to see how well it works.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Oncology
Barcelona, Spain
MD Anderson Cancer Center
Oncology
Chamartín, Spain
Hospital General Universitario Gregorio Maranon
Oncology
Ciudad Lineal, Spain
Sponsor: Oncomatryx Biopharma S.L.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.